The Diabetes Duet: Developing a Collaborative Care Plan in Concert with Your Patient to Reduce Risk and Improve Outcomes.
AAFP—SEPTEMBER 2014
Panel References 

Panel 1:

1. Association AD. Standards of medical care in diabetes-2013. Diabetes Care. 2013;
   Jan 2013:36(Suppl 1):S11-66.
2. Centers for Disease Control and Prevention DoDT, National Center for Chronic Disease Prevention and Health Promotion. National Diabetes Statistics Report, 2014. http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf2014.
3. Diabetes Numbers At-a-Glance 2011, For Non-Pregnant Adults. National Diabetes Education Program (NDEP), March 2011. NIH.

Panel 2:

1. Manning S, Pucci A, Finer N. Pharmacotherapy for obesity: novel agents and paradigms. Therapeutic advances in chronic disease. May 2014;5(3):135-148.
2. Shekelle P, Morton S, Maglione M, al. e. Pharmacological and Surgical Treatment of Obesity. Summary, Evidence Report/Technology Assessment: Number 103. http://www.ahrq.gov/clinic/epcsums/obesphsum.htm: Agency for Healthcare Research and Quality, Rockville, MD;2004. AHRQ Publication Number 04-E028-1, July 2004.

Panel 3:

1. American Diabetes Association. Standards of medical care in diabetes--2014. Diabetes Care. Jan 2014;37 Suppl 1:S14-80.
2. Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes. Sep 2002;51(9):2796-2803.
3. Chiasson JL, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. Jun 15 2002;359(9323):2072-2077.
4. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. The New England journal of medicine. Feb 7 2002;346(6):393-403.
5. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care. Apr 1997;20(4):537-544.
6. Ramachandran A, Snehalatha C, Mary S, et al. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia. Feb 2006;49(2):289-297.
7. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. The New England journal of medicine. May 3 2001; 344(18):1343-1350.

Panel 4:

1. American Diabetes Association. Standards of medical care in diabetes--2014. Diabetes Care.
   Jan 2014;37 Suppl 1:S14-80.
   

Panel 5:

1. American Diabetes Association. Standards of medical care in diabetes--2014. Diabetes Care.
   Jan 2014;37 Suppl 1:S14-80.
2. Herman WH, Hoerger TJ, Brandle M, et al. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of internal medicine. Mar 1 2005;142(5):323-332.
3. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. The New England journal of medicine. Feb 7 2002;346(6):393-403.
4. Li G, Zhang P, Wang J, et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet. May 24 2008;371(9626):1783-1789.
5. Lindstrom J, Ilanne-Parikka P, Peltonen M, et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet. Nov 11 2006;368(9548):1673-1679.

Panel 6:

1. American Diabetes Association. Standards of medical care in diabetes--2014. Diabetes Care.
   Jan 2014;37 Suppl 1:S14-80.

Panel 7:

1. American Diabetes Association. Standards of medical care in diabetes--2014. Diabetes Care.
   Jan 2014;37 Suppl 1:S14-80.

One Size Does Not Fit All: Developing a Collaborative Care Plan with Your Patient to Reduce Obesity and Improve Outcomes.
AAFP—SEPTEMBER 2014
Panel References 

1. Finkelstein EA, Khavjou OA, Thompson H, et al. Obesity and severe obesity forecasts through 2030. American journal of preventive medicine. Jun 2012;42(6):563-570.
2. Moyer V. U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2012;157(5):373-378.
3. Obesity and Overweight Data for U.S. Adults, Centers for Disease Control Website. Available at: www.cdc.gov/nchs/fastats/obesity-overweight.htm. Accessed: October 8, 2014.
4. Ogden CL,Carroll MD, Kit BK, Flegal KM. Prevalence of obesity in the United States, 2009- 2010. NCHS data brief. Jan 2012(82):1-8.

Panel 1:

1. Spring B, Duncan JM, Janke EA, et al. Integrating technology into standard weight loss treatment: a randomized controlled trial. JAMA internal medicine. Jan 28 2013;173(2):105-111.

Panel 2:

1. Hardcastle SJ, Taylor AH, Bailey MP, Harley RA, Hagger MS. Effectiveness of a motivational interviewing intervention on weight loss, physical activity and cardiovascular disease risk factors: a randomised controlled trial with a 12-month post-intervention follow-up. The international journal of behavioral nutrition and physical activity. 2013;10:40.

Panel 3:

1. Greenway FL, Caruso MK. Safety of obesity drugs. Expert opinion on drug safety.
   Nov 2005;4(6):1083-1095.
2. Hampp C, Kang EM, Borders-Hemphill V. Use of prescription antiobesity drugs in the United States. Pharmacotherapy. Dec 2013;33(12):1299-1307.
3. Heal DJ, Gosden J, Smith SL. A review of late-stage CNS drug candidates for the treatment of obesity. International journal of obesity. Jan 2013;37(1):107-117.
4. hysicians AAoF. Internal Needs Assessment 2014.
5. Samaranayake NR, Ong KL, Leung RY, Cheung BM. Management of obesity in the National Health and Nutrition Examination Survey (NHANES), 2007-2008. Annals of epidemiology. May 2012;22(5):349-353.

Panel 4:

1. Manning S, Pucci A, Finer N. Pharmacotherapy for obesity: novel agents and paradigms. Therapeutic advances in chronic disease. May 2014;5(3):135-148.
2. Shekelle P, Morton S, Maglione M, al. e. Pharmacological and Surgical Treatment of Obesity. Summary, Evidence Report/Technology Assessment: Number 103. http://www.ahrq. gov/clinic/epcsums/obesphsum.htm: Agency for Healthcare Research and Quality, Rockville, MD;2004. AHRQ Publication Number 04-E028-1, July 2004.

Panel 5:

1. Apovian CM. The clinical and economic consequences of obesity. The American journal of managed care. Aug 2013;19(11 Suppl):s219-228.

IDEAL® - American Academy of Family Physicians - September 2013

Links for Resources

Pain Management:
Memorial Pain Assessment Card
http://www.partnersagainstpain.com/printouts/A7012AS9.pdf

MPQ: Mc Gill Pain Questionnaire
http://www.mapi-trust.org/services/questionnairelicensing/catalog-questionnaires/257-mpq

Brief Pain Inventory
http://www.mdanderson.org/education-and-research/departments-programs-and-labs/departments-and-divisions/symptom-research/symptom-assessment-tools/brief-pain-inventory.html

Men’s Health:

American Cancer Society Testing for prostate cancer
http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-024618.pdf

Prosdex A PSA decision aid
www.prosdex.com/index_content.htm

Mayo Clinic Prostate cancer screening: Should you get a PSA test?
www.mayoclinic.com/health/prostate-cancer/ HQ01273

US Preventive Services Task Force Understanding task force recommendations. Screening for prostate cancer
http://www.uspreventiveservicestaskforce.org/prostatecancerscreening/prostatecancerfact.pdf

US Preventive Services Task Force Talking with your patients about screening for prostate cancer http://www.uspreventiveservicestaskforce.org/prostatecancerscreening/prostatecancerscript.pdf

Centers for Disease Control Prostate cancer
http://www.cdc.gov/cancer/dcpc/resources/features/prostatecancer/

Informed Medical Decisions Foundation Deciding if the PSA test is right for you
http://www.informedmedicaldecisions.org/imdf_decision_aid/deciding-if-the-psa-test-is-right-for-you/

MISSION PAIN MANAGEMENT : THE PATIENT-CENTERED APPROACH
AAFP—SEPTEMBER 2013
Panel References 

PANEL 1
American Academy of Family Physicians. PCMH overview—the patient-centered medical home. www.aafp.org/practice-management/pcmh/overview.html. Accessed August 16, 2013.

Chou R, Fanciullo GJ, Fine PG, et al; American Pain Society-American Academy of Pain Medicine Opioids Guidelines Panel. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10(2):113-130.

Shi L, Macinko J, Starfield B, Wulu J, Regan J, Politzer R. The relationship between primary care, income inequality, and mortality in US states, 1980-1995. J Am Board Fam Pract. 2003;16(5):412-422.

PANEL 2
Chou R, Fanciullo GJ, Fine PG, et al; American Pain Society-American Academy of Pain Medicine Opioids Guidelines Panel. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10(2):113-130.

PANEL 3
Adams LL, Gatchel RJ, Robinson RC, et al. Development of a self-report screening instrument for assessing potential opioid medication misuse in chronic pain patients. J Pain Symptom Manage. 2004;27(5):440-459.

Belgrade MJ, Schamber CD, Lindgren BR. The DIRE score: predicting outcomes of opioid prescribing for chronic pain. J Pain. 2006;7(9):671-681.

Bittner BL, Marcus DA, Tenzer P. Using opioids in the management of chronic pain patients: challenges and future options. American Academy of Family Physicians, 2010. http://www.mc.uky.edu/equip-4-pcps/documents/CRx%20Literature/Opioids%20for%20chronic%20pain.pdf. Accessed August 15, 2013.

Butler SF, Budman SH, Fernandez K, Jamison RN. Validation of a screener and opioid assessment measure for patients with chronic pain. Pain. 2004;112(1-2):65-75.

Butler SF, Budman SH, Fernandez KC, et al. Development and validation of the Current Opioid Misuse Measure. Pain. 2007;130(1-2):144-156.

Butler SF, Fernandez K, Benoit C, Budman SH,  Jamison RN. Validation of the revised Screener and Opioid Assessment for Patients with Pain (SOAPP-R). J Pain. 2008;9(4):360-372.

Coambs RB, Jarry JL. The SISAP: a new screening instrument for identifying potential opioid abusers in the management of chronic nonmalignant pain in general medical practice. Pain Res Manage. 1996;1:155-162.

Gatchel RJ. Methods for monitoring medication use in chronic pain patients. Adv Pain Manage. 2008;2(2):54-58. http://www.cecentral.com/assets/817/men08061-04_content_FINAL.pdf. Accessed August 15, 2013.

Johnson, K. Opioid misuse screening underused by GPs. Medscape News, September 13, 2012. http://www.medscape.com/viewarticle/770839. Accessed August 15, 2013.

Passik SD, Kirsh KL. Appropriate prescribing of opioids and associated risk minimization. Adv Pain Manage. 2008;2(1):9-16. http://www.cecentral.com/assets/816/men08061-01_content_web_FINAL.pdf. Accessed August 15, 2013.

Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool. Pain Med. 2005;6(6):432-442.

PANEL 4
Bittner BL, Marcus DA, Tenzer P. Using opioids in the management of chronic pain patients: challenges and future options. American Academy of Family Physicians, 2010. http://www.mc.uky.edu/equip-4-pcps/documents/CRx%20Literature/Opioids%20for%20chronic%20pain.pdf. Accessed August 15, 2013.

Chou R, Fanciullo GJ, Fine PG, et al; American Pain Society-American Academy of Pain Medicine Opioids Guidelines Panel. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10(2):113-130.

Stanos S. Use of opioids. J Fam Pract. 2007;56(2 suppl pain):23-32.

PANEL 5
Chou R, Fanciullo GJ, Fine PG, et al; American Pain Society-American Academy of Pain Medicine Opioids Guidelines Panel. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10(2):113-130.

US Food and Drug Administration. FDA blueprint for prescriber education for extended-release and long-acting opioid analgesics. Reference ID: 3292572. http://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM277916.pdf. Published April 2013. Accessed August 18, 2013.

US Food and Drug Administration. Opioid drugs and Risk Evaluation and Mitigation Strategies (REMS): November 2009 update. http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm226958.htm. Updated September 23, 2010. Accessed August 16, 2013.

Webster LR. Eight principles for safer opioid prescribing. Pain Med. 2013;14(7):959-961.

PANEL 6
Chou R, Fanciullo GJ, Fine PG, et al; American Pain Society-American Academy of Pain Medicine Opioids Guidelines Panel. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10(2):113-130.

Fine PG, Portenoy RK; Ad Hoc Expert Panel on Evidence Review and Guidelines for Opioid Rotation. Establishing “best practices” for opioid rotation: conclusions of an expert panel. J Pain Symptom Manage. 2009;38(3):418-425.

Mercadante S, Bruera E. Opioid switching: a systematic and critical review. Cancer Treat Rev. 2006;32(4):304-315.

Mercadante S, Ferrera P, Villari P, Casuccio A, Intravaia G, Mangione S. Frequency, indications, outcomes, and predictive factors of opioid switching in an acute palliative care unit. J Pain Symptom Manage. 2009;37(4):632-641.

Pereira J, Lawlor P, Vigano A, Dorgan M, Bruera E. Equianalgesic dose ratios for opioids: a critical review and proposals for long-term dosing. J Pain Symptom Manage. 2001;22(2):672-687.

Webster LR, Fine PG. Review and critique of opioid rotation practices and associated risks of toxicity. Pain Med. 2012;13(4):562-570.

 

PANEL 7
Katz NP, Sherburne S, Beach M, et al. Behavioral monitoring and urine toxicology testing in patients receiving long-term opioid therapy. Anesth Analg. 2003;97(4):1097-1102.

Passik SD, Kirsh KL. Appropriate prescribing of opioids and associated risk minimization. Adv Pain Manage. 2008;2(1):9-16. http://www.cecentral.com/assets/816/men08061-01_content_web_FINAL.pdf. Accessed August 15, 2013.

Passik SD, Kirsh KL, McDonald MV, et al. A pilot survey of aberrant drug-taking attitudes and behaviors in samples of cancer and AIDS patients. J Pain Symptom Manage. 2000;19(4):274-286.

Passik SD, Weinreb HJ. Managing chronic nonmalignant pain: overcoming obstacles to the use of opioids. Adv Ther. 2000;17(2):70-83.

Hit Below the Belt: Winning Strategies to Combat Men’s Health Issues
AAFP—SEPTEMBER 2013
Panel References 

PANEL 1
American Academy of Family Physicians.AAFP Reprint No. 257, 2010. Recommended Curriculum Guidelines for Family Medicine Residents – Men’s Health. http://www.aafp.org/dam/ AAFP/documents/medical_education_residency/program_directors/Reprint257_ Men.pdf. Accessed August 14, 2013.

Dobs AS. Hypogonadism treatment considerations, monitoring, and followup. Paper presented at: TU 1st Annual Conference on Improving Clinical Outcomes in Hypogonadism; November 3, 2007. http://primaryperspective.org/tu/1st_Clin_Conf_06_02_08.pdf. Accessed August 14,2013. Lin GA, Aaronson DS, Knight SJ, Carroll PR, Dudley RA. Patient decision aids for prostate cancer treatment: a systematic review of the literature. CA Cancer J Clin. 2009;59(6):379-390. Searight R. Realistic approaches to counseling in the office setting. Am Fam Physician. 2009;79(4):277-284.

Tudiver F, Talbot Y. Why don’t men seek help? Family physicians’ perspectives on help-seeking behavior in men. J Fam Pract. 1999;48(1):47-52.

PANEL 2
Basch E, Oliver TK, Vickers A, et al. Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology Provisional Clinical Opinion. J Clin Oncol. 2012;30(24):3020-3025.

Carter HB, Albertsen PC, Barry MJ, et al. Early detection of prostate cancer: AUA guideline. J Urol. 2013;190(2):419-426.

Moyer VA; U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157(2):120-134.

Qaseem A, Barry MJ, Denberg TD, Owens DK, Shekelle P; Clinical Guidelines Committee of the American College of Physicians. Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med. 2013;158(10):761-769.

Schröder FH, Hugosson J, Carlsson S, et al. Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC).Eur Urol. 2012;62(5):745-752.
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10-29.

Wolf AM, Wender RC, Etzioni RB, et al; American Cancer Society Prostate Cancer Advisory Committee. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin. 2010;60(2):70-98.

PANEL 3
Basch E, Oliver TK, Vickers A, et al. Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology Provisional Clinical Opinion. J Clin Oncol. 2012;30(24):3020-3025.
Carter HB, Albertsen PC, Barry MJ, et al. Early detection of prostate cancer: AUA guideline. J Urol.

2013;190(2):419-426.
Lin GA, Aaronson DS, Knight SJ, Carroll PR, Dudley RA. Patient decision aids for prostate cancer treatment: a
systematic review of the literature. CA Cancer J Clin. 2009;59(6):379-390.
Wolf AM, Wender RC, Etzioni RB, et al; American Cancer Society Prostate Cancer Advisory Committee.

American Cancer Society guideline for the early detection of prostate cancer update: update 2010. CA Cancer
J Clin. 2010;60(2):70-98.

PANELS 4,5,6,7,8
Bhasin S, Cunningham GR, Hayes FJ, et al; Task Force, Endocrine Society. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab.
2010;95(6):2536-2559.

Ideal^® • Copyright 2013